pandem
influenza
viral
infect
continu
public
health
threat
overal
case
fatal
rate
low
approxim
hospit
patient
requir
admiss
intens
care
unit
icu
sever
patient
fatal
outcom
understand
pathogen
event
lead
critic
pandem
import
design
better
strategi
prevent
treatment
sever
outcom
previou
studi
examin
host
immun
respons
emerg
virus
sever
acut
respiratori
syndrom
sar
associ
coronaviru
suggest
sever
diseas
character
malfunct
switch
innat
adapt
immun
respons
viru
similar
sever
infect
caus
influenza
viru
dysregul
cytokin
secret
describ
sever
case
infect
pandem
influenza
viru
caus
defect
host
respons
pneumonia
show
ex
vivo
cultur
peripher
blood
mononuclear
cell
pandem
influenza
patient
ferret
infect
pandem
influenza
viru
recoveri
infect
improv
clinic
sign
parallel
switch
innat
adapt
phase
host
immun
respons
potenti
use
gene
signatur
better
assess
immunopatholog
clinic
manag
sever
viral
infect
wide
demonstr
past
use
system
biologybas
approach
analyz
respons
viral
infect
follow
hospit
critic
ill
patient
admit
seven
spanish
intens
care
unit
result
indic
pandem
patient
sever
respiratori
diseas
poor
outcom
character
impair
activ
gene
particip
develop
antivir
adapt
respons
nineteen
patient
attend
particip
icu
primari
viral
pneumonia
acut
phase
influenza
viru
ill
acut
respiratori
distress
unequivoc
alveolar
opacif
involv
two
lobe
neg
respiratori
blood
bacteri
cultur
admiss
recruit
novemb
decemb
patient
older
year
younger
year
exclud
studi
avoid
immaturityag
immun
system
confus
factor
analysi
patient
confirm
infect
realtim
polymeras
chain
reaction
pcr
includ
studi
n
serial
blood
sampl
plasma
serum
rna
collect
use
serum
ethylenediaminetetraacet
acid
edta
paxgen
bd
venou
blood
vacuum
collect
follow
manufactur
instruct
day
admiss
icu
accord
unifi
protocol
particip
center
pharyng
sampl
collect
parallel
fifteen
healthi
volunt
similar
age
patient
recruit
worker
univers
valladolid
spain
standard
survey
employ
collect
clinic
data
includ
histori
physic
examin
oximetr
measur
hematolog
biochem
radiolog
microbiolog
investig
particip
center
treatment
decis
patient
includ
corticosteroid
therapi
standard
decid
attend
physician
inform
consent
obtain
directli
patient
legal
repres
also
healthi
control
enrol
patient
control
identif
remain
anonym
approv
studi
protocol
scientif
ethic
aspect
obtain
scientif
committe
clinic
research
one
particip
center
sampl
store
cytokin
antibodi
rnam
profil
attend
time
seroconvers
product
antibodi
day
onset
symptom
consid
border
innat
adapt
immun
respons
patient
establish
two
moment
evolut
diseas
earli
phase
onset
symptom
day
day
late
phase
day
patient
divid
two
group
depend
respiratori
statu
mv
group
need
invas
mechan
ventil
follow
admiss
nmv
group
compos
patient
need
mechan
ventil
moment
hospit
cytokin
gene
express
viral
load
mv
patient
compar
nmv
patient
earli
late
phase
separ
number
sampl
analyz
phase
detail
addit
file
viral
diagnosi
perform
rna
pharyng
swab
microbiolog
servic
particip
hospit
revers
transcriptionpolymeras
chain
reaction
rtpcr
base
method
use
reagent
provid
free
charg
center
diseas
control
cdc
atlanta
ga
usa
purchas
roch
basel
switzerland
detect
set
sampl
also
assess
multiplex
pcr
luminex
xtag
rvp
kit
luminexabbott
coinfect
respiratori
syncyti
viru
influenza
b
viru
parainfluenza
virus
human
metapneumoviru
enterovirus
rhinoviru
adenoviru
bocaviru
coronavirus
accord
manufactur
instruct
viral
load
quantifi
pharyng
swab
plasma
virolog
lab
whoassoci
center
hospit
clinic
barcelona
spain
detail
addit
file
oseltamivir
resist
directli
detect
initi
posit
pharyng
swab
rtpcr
sequenc
fragment
neuraminidas
gene
presenc
mutat
use
abi
genet
analyz
hai
assay
perform
aliquot
sampl
univers
health
network
uhn
toronto
ontario
canada
sera
treat
receptordestroy
enzym
rde
v
cholera
dilut
one
part
serum
three
part
enzym
incub
overnight
water
bath
enzym
inactiv
incub
follow
addit
six
part
physiolog
salin
final
dilut
hi
assay
perform
vbottom
microtit
plate
corn
costar
co
cambridg
usa
turkey
erythrocyt
previous
describ
use
inactiv
pandem
influenza
antigen
microarray
perform
univers
health
network
uhn
toronto
ontario
canada
detail
explan
microarray
assay
provid
addit
file
ingenu
pathway
analysi
ipa
ingenu
system
redwood
citi
ca
usa
use
select
annot
visual
gene
function
pathway
gene
ontolog
ipa
analysi
identifi
canon
pathway
differenti
express
p
comparison
group
hierarch
cluster
gene
differenti
express
group
ipa
analysi
perform
use
brbarray
tool
stabl
releas
develop
dr
richard
simon
brbarray
tool
develop
team
result
microarray
data
set
upload
geo
microarray
data
repositori
geo
verifi
chang
microarray
gene
express
use
quantit
realtim
pcr
qrtpcr
repres
gene
analysi
figur
addit
file
primer
specif
human
gapdh
mrna
use
normal
sampl
immun
mediat
level
serum
measur
patient
control
use
multiplex
biorad
assay
hercul
ca
usa
infect
immun
unit
hospit
universitarioiecscyl
valladolid
spain
system
allow
quantit
measur
differ
chemokin
cytokin
growth
factor
immun
mediat
consum
small
amount
biolog
materi
number
addit
solubl
mediat
measur
use
enzymelink
inmunosorb
assay
elisa
interferon
verikin
kit
purchas
pbl
interferon
sourc
piscataway
nj
usa
quantikin
kit
purchas
r
system
minneapoli
mn
usa
legend
max
kit
purchas
biolegend
san
diego
ca
usa
immun
mediat
concentr
individu
sampl
normal
median
concentr
control
group
n
result
ratio
compar
group
patient
mannwhitney
u
test
employ
cytokin
comparison
purpos
sinc
saphiro
wilk
test
evidenc
absenc
normal
distribut
data
leven
test
demostr
absenc
homogen
varianc
mv
nmv
group
correl
studi
cytokin
level
gene
express
level
viral
load
clinic
paramet
done
calcul
spearman
correl
coeffici
statist
test
twosid
p
consid
signific
patient
posit
admiss
intens
care
unit
icu
absenc
respiratori
viru
pharyng
swab
none
patient
receiv
vaccin
patient
receiv
oseltamivir
therapi
day
admiss
icu
none
viral
sampl
examin
show
mutat
confer
resist
oseltamivir
twelv
patient
show
respiratori
work
sever
enough
need
invas
mechan
ventil
icu
admiss
patient
classifi
mv
group
none
remain
seven
mechan
ventil
hospit
patient
classifi
nmv
group
common
symptom
onset
fever
case
mv
case
nmv
myalgia
cough
dyspnea
nine
patient
sever
group
six
less
sever
one
concomit
preexist
condit
tabl
none
patient
except
one
patient
nmv
group
receiv
treatment
bortezomib
immunosuppressori
therapi
day
admiss
five
mv
patient
four
seven
patient
nmv
group
receiv
steroid
time
sampl
collect
tabl
seven
mv
patient
fail
recov
diseas
die
mean
ill
durat
time
day
mean
sd
nmv
patient
recov
diseas
lead
caus
death
primari
respiratori
failur
refractori
hypoxemia
five
patient
multiorgan
failur
remain
two
patient
tabl
addit
file
differ
found
viral
load
mv
nmv
patient
earli
stage
diseas
mv
patient
show
significantli
higher
viral
load
nmv
pharynx
late
stage
diseas
p
figur
three
mv
patient
one
nmv
show
detect
viremia
day
icu
admiss
undetect
viru
plasma
afterward
viral
load
pharynx
show
direct
correl
sofa
score
r
invers
one
satur
r
cours
diseas
five
mv
patient
suffer
bacteri
fungal
superinfect
point
hospit
tabl
three
patient
suffer
bacteri
superinfect
die
tabl
addit
file
remark
none
patient
nmv
group
suffer
bacteri
superinfect
three
patient
two
mv
one
nmv
produc
antibodi
hai
titer
last
day
sampl
collect
seroconvers
took
place
day
onset
symptom
mv
group
day
nmv
group
mean
sd
signific
differ
two
group
comparison
gene
express
profil
mv
nmv
patient
earli
phase
diseas
reveal
absenc
differenti
express
gene
group
hand
comparison
late
phase
diseas
reveal
gene
differenti
express
mv
nmv
patient
p
fdr
ipa
analysi
identifi
late
phase
signific
depress
group
intracellular
signal
pathway
import
develop
antivir
immun
respons
sever
group
patient
mv
compar
nmv
group
figur
number
gene
involv
antigen
present
figur
b
cell
develop
figur
addit
file
signal
helper
cell
figur
addit
file
granzym
b
signal
figur
addit
file
helper
cell
differenti
protein
ubiquitin
dendrit
cell
matur
apoptosi
bcell
receptor
bcr
signal
differenti
regul
two
group
significantli
lower
mv
group
contrari
mv
group
show
significantli
higher
express
signal
pathway
figur
addit
file
tabl
addit
file
show
gene
differenti
express
group
classifi
individu
pathway
ipa
identifi
signal
pathway
differenti
express
seven
mv
patient
fatal
outcom
remain
five
surviv
infect
express
level
hladma
hladmb
show
neg
correl
viral
load
pharynx
late
phase
diseas
p
r
gene
except
correl
posit
satur
phase
p
r
show
also
neg
associ
sofa
score
sever
also
hlac
p
r
nmv
mv
group
show
major
differ
cytokin
chemokin
profil
earli
phase
diseas
tabl
addit
file
howev
late
phase
mv
patient
show
significantli
higher
level
chemokin
figur
tabl
addit
file
late
phase
mv
patient
show
higher
level
two
key
cytokin
relat
cytokin
also
two
cellular
growth
factor
vegf
gmcsf
less
sever
patient
nmv
also
late
phase
mv
patient
show
increas
level
two
immunomodulatori
cytokin
figur
tabl
addit
file
level
show
posit
correl
viral
load
pharynx
cours
diseas
p
r
coeffici
gmcsf
show
posit
correl
sofa
score
sever
p
r
coeffici
level
show
invers
associ
express
level
show
invers
associ
hlac
express
level
p
r
undetect
vast
major
patient
group
along
cours
diseas
examin
host
immun
respons
sever
patient
requir
admiss
icu
basi
presenc
antibodi
abl
identifi
two
phase
diseas
sever
patient
earli
phase
character
absenc
antibodi
innat
immun
phase
later
phase
defin
presenc
circul
antibodi
adapt
immun
phase
analysi
gene
express
cytokin
profil
led
character
signatur
associ
diseas
sever
poor
outcom
late
phase
impair
express
number
mhc
class
ii
dm
dp
dq
dr
mhc
class
hlac
gene
cell
receptorassoci
gene
also
group
gene
particip
dendrit
cell
matur
point
exist
defect
antigen
present
sever
group
patient
need
mechan
ventil
mv
late
phase
adapt
immun
adequ
antigen
present
need
develop
effect
adapt
immun
influenza
virus
circumst
chang
affect
antigen
present
strongli
impact
viral
kinet
host
viral
immun
factor
disrupt
antigen
present
prevent
effect
adapt
immun
respons
evid
potenti
role
alter
antigen
present
develop
appropri
adapt
respons
viru
come
impair
express
group
gene
pivot
activ
function
b
cell
observ
mv
group
late
phase
defect
express
mhc
class
ii
molecul
support
impair
helper
cell
differenti
signal
group
patient
poor
express
fyn
mhc
class
ii
molecul
gene
indic
disrupt
signal
helper
cell
need
effect
primari
tcell
expans
impair
express
dffa
endog
prkdc
affect
granzym
b
signal
pathway
involv
induct
apoptosi
virusinfect
cell
cytotox
lymphocyt
ctl
impair
helper
cell
differenti
granzym
b
signal
along
poor
express
cell
receptor
associ
gene
support
defect
cell
respons
phase
adapt
immun
mv
group
moreov
poor
express
gene
relat
b
cell
develop
b
cell
receptor
signal
mhc
class
ii
molecul
hra
point
alter
b
cell
function
key
period
host
respons
viru
addit
clue
exist
defect
adapt
respons
sever
pandem
influenza
come
impair
express
group
gene
particip
apoptosi
signal
pathway
dffa
endog
hra
tp
sinc
apoptosi
recogn
antivir
mechan
defect
apoptosi
could
translat
poor
control
viru
addit
defect
express
sever
ubiquitinconjug
enzym
ubiquitinspecif
peptidas
demonstr
ubiquitin
also
affect
sever
pandem
influenza
phase
adapt
respons
ubiquitin
regul
develop
mani
phase
immun
respons
includ
initi
propag
termin
alter
pathway
sever
pandem
influenza
could
affect
consequ
step
need
develop
appropri
respons
viru
role
steroid
immunosuppressor
drug
genesi
impair
adapt
respons
limit
sinc
none
patient
sever
group
immunosuppressor
treatment
admiss
date
addit
detail
tabl
proport
patient
steroid
treatment
moment
sampl
collect
hospit
period
similar
group
patient
mv
nmv
consequ
steroid
treatment
affect
similarli
group
term
modul
immun
respons
abil
show
vast
major
patient
mv
group
produc
specif
antibodi
indic
antibodi
gener
insuffici
overcom
infect
result
gene
express
support
defect
cellular
immun
basi
poor
control
viru
group
well
known
helper
ctl
respons
play
determin
role
contain
influenza
infect
occur
group
design
studi
aim
clarifi
particip
cellular
respons
sever
diseas
caus
hand
patient
mv
group
show
higher
express
level
gene
particip
canon
pathway
phase
adapt
immun
pathway
play
opposit
role
proinflammatori
antiinflammatori
respect
addit
serum
level
protein
highest
mv
group
phase
group
show
also
elev
level
chemokin
cytokin
growth
factor
presenc
hypercytokinemia
recent
report
infect
describ
also
fatal
diseas
sever
sar
acut
rsv
bronchiol
sepsi
posit
associ
chemokin
cytokin
viral
load
studi
evid
marker
ongo
viral
replic
previous
observ
sar
infect
high
level
immunomodulatori
molecul
could
repres
attempt
prevent
cytokinedriven
inflammatori
damag
altern
virusinduc
evas
mechan
posit
correl
observ
viral
load
sofa
neg
correl
cytokin
express
level
gene
particip
antigen
present
pathway
support
role
mediat
favor
viral
replic
detail
tabl
bacteri
superinfect
took
place
earli
late
cours
diseas
support
role
impair
adapt
respons
releas
immunosuppressori
cytokin
increas
incid
bacteri
superinfect
observ
sever
diseas
follow
infect
find
suggest
state
host
adapt
immun
defici
haid
patient
sever
pandem
influenza
lead
unremit
cycl
viral
replic
innat
cytokinechemokin
releas
figur
scenario
haid
resembl
concept
immunoparalysi
describ
sepsi
interrupt
deleteri
cycl
may
lead
improv
diseas
outcom
associ
host
immun
respons
clinic
outcom
sever
pandem
influenza
poorli
known
potenti
use
gene
signatur
better
assess
immunopatholog
clinic
manag
sever
viral
infect
wide
demonstr
past
previou
studi
examin
host
gene
express
profil
emerg
virus
sarsassoci
coronaviru
suggest
sever
diseas
character
malfunct
switch
innat
adapt
immun
respons
viru
similar
sever
infect
caus
influenza
viru
dysregul
cytokin
secret
describ
sever
case
pandem
patient
sever
respiratori
diseas
poor
outcom
character
impair
activ
gene
particip
develop
antivir
adapt
respons
persist
viru
respiratori
tract
find
suggest
state
haid
resembl
concept
immunoparalysi
describ
sepsi
haid
coexist
persist
releas
cytokin
patient
poorest
outcom
result
support
idea
haid
would
lead
unremit
cycl
viral
replic
innat
cytokinechemokin
releas
interrupt
deleteri
cycl
antivir
andor
immunomodulatori
therapi
may
lead
improv
diseas
outcom
fgfb
human
fibroblast
growth
factorbas
gcsf
granulocyt
colonystimul
factor
gmcsf
granulocyt
macrophag
colonystimul
factor
haid
host
adapt
immun
defici
interleukin
receptor
antagonist
interferoninduc
monocyt
chemoattract
macrophag
inflammatori
macrophag
inflammatori
new
variant
influenza
viru
pdgfbb
plateletderiv
growth
factor
rsv
respiratori
syncyti
viru
sar
sever
acut
respiratori
syndrom
sofa
sepsisrel
organ
failur
assess
tumor
necrosi
factor
vegf
vascular
endotheli
growth
factor
author
declar
compet
interest
jfbm
iml
jr
rol
assist
design
studi
coordin
patient
recruit
analyz
interpret
data
assist
write
paper
dk
assist
design
studi
analyz
interpret
data
assist
write
paper
aa
tp
mam
mcg
vf
dv
bn
sro
cc
perform
virolog
work
ra
glc
fm
lr
charg
bioinformat
analysi
pr
ls
al
da
em
mjg
mg
sa
cl
pm
jb
fg
fb
supervis
clinic
aspect
particip
patient
recruit
assist
analysi
interpret
data
write
report
db
dcn
develop
hai
assay
assist
analysi
data
lr
lx
vi
carri
microarray
data
cytokin
profil
sampl
process
sre
assist
statist
analysi
